GHB and Related Compounds

Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, Fourth Edition

Volumn , Issue , 2007, Pages 803-823

  Quang, Lawrence S ^a,b,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Greater Cleveland Poison Control Center   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960802352     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0693-4.50051-7     Document Type: Chapter

References (274)

1. Close Call. Retrieved January 2005 from http://espn.go.com/magazine/vol3no7gugliotta.html.
2. CBS News: Nick Nolte cops a plea. Retrieved January 2005 from http://www.cbsnews.com/stories/2002/10/24/entertainment/main526796.shtml.
3. CNN: Max Factor heir returns to face prison term. Retrieved January 2005 from http://www.cnn.com/2003/LAW/06/19/max.factor.heir/.
4. CBS News: Fugitive Max Factor heir caught. Retrieved January 2005 from http://www.cbsnews.com/stories/2003/06/19/national/main559376.shtml.
5. Centers for Disease Control and Prevention (1990) Multistate outbreak of poisonings associated with illicit use of gamma hydroxybutyrate. MMWR 39 861-863.
6. JE Dyer (1991) Gammahydroxybutyrate: a health food product producing coma and seizure-like activity. Am J Emerg Med 9 321-324.
7. Food and Drug Administration: Gamma hydroxybutyric acid. Press Release P90-53. Rockville, MD, Food and Drug Administration, November 8, 1990.
8. TF Higgins and SW Borron (1996) Coma and respiratory arrest after exposure to butyrolactone. J Emerg Med 14 435-437.
9. National Institute on Drug Abuse: Club Drugs. Retrieved January 2005 from http://www.drugabuse.gov/drugpages/clubdrugs.html.
10. NJ Giacamino and EL McCawley (1947) On the toxic reactions of unsaturated lactones and their saturated analogs. Fed Proc 6 331-332.
11. BA Rubin and NJ Giarman (1947) The therapy of experimental influenza in mice with antibiotic lactones and related compounds. Yale J Biol Med 19 1017-1024.
12. H Laborit, JM Jouany, J Gerard, et al. (1960) Generalities concerning the experimental study and clinical use of gamma hydroxybutyrate of Na [French]. Agressologie 1 397-406.
13. H Laborit, F Buchard, G Laborit, et al. (1960) Use of sodium 4-hydroxybutyrate in anesthesia and resuscitation [French]. Agressologie 1 549-560.
14. H Laborit, JM Jouany, J Gerard, et al. (1960) Summary of an experimental and clinical study on a metabolic substrate with inhibitory central action: sodium 4-hydroxybutyrate [French]. Presse Med 68 1867-1869.
15. SP Bessman and WN Fishbein (1963) Gamma hydroxybutyrate a new metabolite in brain [Letter]. FASEB J 22 334.
16. SP Bessman and WN Fishbein (1963) Gammahydroxybutyrate, a normal brain metabolite. Nature 200 1207-1208.
17. H Sprince, JA Josephs and CR Wilpizeski (1966) Neuropharmacological effects of 1,4-butanediol and related congeners compared with those of gammahydroxybutyrate and gamma-butyrolactone. Life Sci 5 2041-2052.
18. M Blumenfeld, RG Suntay and MH Harmel (1962) Sodium gamma-hydroxybutyric acid: a new anaesthetic adjuvant. Anesth Analg 41 721-726.
19. J Solway and MS Sadove (1965) 4-Hydroxybutyrate: a clinical study. Anesth Analg 44 532-539. 1965.
20. S Kleinschmidt, U Grundmann, U Janneck, et al. (1997) Total intravenous anesthesia using propofol, gammahydroxybutyrate or midazolam in combination with sufentanil for patients undergoing coronary artery bypass surgery. Eur J Anaesthesiol 14 590-599.
21. S Kleinschmidt, U Grundmann, T Knocke, et al. (1998) Total intravenous anaesthesia with gammahydroxybutyrate (GHB) and sufentanil in patients undergoing coronary artery bypass graft surgery: a comparison in patients with unimpaired and impaired left ventricular function. Eur J Anaesthesiol 15 559-564.
22. S Kleinschmidt, C Schellhase and F Mertzufft (1999) Continuous sedation during spinal anaesthesia: gammahydroxybutyrate vs propofol. Eur J Anaesthesiol 16 23-30.
23. J Takahara, S Yunoki, W Yakushiji, et al. (1977) GHB Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 44(5), 1014-1017.
24. MO Rambourg-Schepens, M Buffet, C Durak, et al. (1997) Gamma butyrolactone poisoning and its similarities to gamma-hydroxybutyric acid: two case reports. Vet Hum Toxicol 39 234-235.
25. F LoVecchio, SC Curry and T Bagnasco (1998) Butyrolactone-induced central nervous system depression after ingestion of Renewtrient. a “dietary supplement.” N Engl J Med 339 847-848.
26. Centers for Disease Control and Prevention (1999) Adverse effects associated with ingestion of gamma-butyrolactone. Minnesota, New Mexico, and Texas, 1998–1999. MMWR 48(7), 137-140.
27. CJ Hardy, NR Slifman, KC Klontz, et al. (1999) Adverse events reported with the use of gamma-butyrolactone products marketed as dietary supplements [Abstract]. J Toxicol Clin Toxicol 37(5), 650.
28. Food and Drug Administration: FDA Talk Paper: FDA warns about products containing gamma butyrolactone or GBL and asks companies to issue a recall. Retrieved January 2005 from http://www.fda.gov/bbs/topics/ANSWERS/ANS00937.html.
29. Food and Drug Administration: FDA Talk Paper: FDA warns about GBL-related products. Retrieved January 2005 from http://www.fda.gov/bbs/topics/ANSWERS/ANS00953.html.
30. FP Kohrs and WH Porter (1999) Gammahydroxybutyrate intoxication and overdose. Ann Emerg Med 33(4), 475-476.
31. JP Winickoff, CS Houck, EL Rothman, et al. (2000) Experience and reason: Verve and Jolt: Deadly new internet drugs. Pediatrics 106(4), 829-830.
32. F Leblanc and R Blais (2000) Gamma butyrolactone exposure from nail polish remover [Abstract]. J Toxicol Clin Toxicol 38(5), 535.
33. EW Boyer, D Fearon, AC Anderson, et al. (2000) Child neglect leading to gammahydroxybutyrate ingestion [Abstract]. J Toxicol Clin Toxicol 38(5), 534-535.
34. L Vandevenne, J Beckers, E Van de Velde, et al. (2000) A case of gamma-butyrolactone overdose [Abstract]. J Toxicol Clin Toxicol 38(2), 227.
35. M Eckstein, SO Henderson, P DelaCruz, et al. (1999) Gamma hydroxybutyrate (GHB): report of a mass intoxication and review of the literature. Prehosp Emerg Care 3(4), 357-361.
36. J Cisek, C Holstege and R Rose (1999) Seizure associated with butanediol ingestion [Abstract]. J Toxicol Clin Toxicol 37(5), 650.
37. Food and Drug Administration: Medwatch—More on GBL, GHB, BD. Retrieved January 2005 from http://www.fda.gov/medwatch/SAFETY/1999/gblghb.htm.
38. M Shannon and LS Quang (2000) Gammahydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. Pediatr Emerg Care 16(6), 435-440.
39. M Ingels, C Rangan, J Bellezzo, et al. (2000) Coma and respiratory depression following the ingestion of GHB and it precursors: three cases. J Emerg Med 19(1), 47-50.
40. T Schneidereit, K Burkhart, JW Donovan, et al. (2000) Butanediol toxicity delayed by preingestion of ethanol. Int J Med Toxicol 3(1), 1-3.
41. J Kraner, J Plassard, D McCoy, et al. (2000) Fatal overdose from ingestion of 1,4-butanediol, a GHB precursor [Abstract]. J Toxicol Clin Toxicol 38(5), 534.
42. DL Zvosec, SW Smith, JD McCutcheon, et al. (2001) Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 344(2), 87-94.
43. Drug Enforcement Agency, Department of Justice (2000) Schedules of controlled substances: addition of gamma hydroxybutyric acid to schedule I. Fed Reg 65 13235-13238.
44. Drug Enforcement Administration, Department of Justice (2000) Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802 (34)): final rule. Fed Reg 65(79), 21645-21647.
45. WA Watson, TL Litovitz, W Klein-Schwartz, et al. (2004) 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 22(5), 335-404.
46. Substance Abuse and Mental Health Services Administration, Office of Applied Studies (2003) Emergency department trends from the Drug Abuse Warning Network, final estimates 1995–2002, DAWN Series: D-24. DHHS publication no. (SMA) 03–3780 Rockville, MD: Department of Health and Human Services
47. Community Epidemiology Work Group, National Institutes of Health, National Institute on Drug Abuse: Epidemiologic trends in drug abuse, advance report, June 2001. Retrieved July 2004 from http://www.nida.nih.gove/CEWG/AdvanceRep/601ADV/601adv.html.
48. Substance Abuse and Mental Health Services Administration, Office of Applied Studies (March 2002) The DAWN report: club drugs 2001 update. Drug Abuse Warning Network Rockville, MD: Department of Health and Human Services
49. LD Johnston, PM O'Malley and JG Bachman (2003) Monitoring the future national results on adolescent drug use: overview of key findings, 2002. NIH publication no. 03–5374 Bethesda, MD: National Institute on Drug Abuse
50. United Nations Commission on Narcotic Drugs: Implementation of the international drug control treaties: changes in the scope of control of substances. Retrieved December 2004 from http://www.unodc.org/pdf/document_2001-01-29_1.pdf.
51. GP Galloway, SL Frederick-Osbourne, R Seymour, et al. (2000) Abuse and therapeutic potential of gamma-hydroxybutyric acid. Alcohol 20 263-269.
52. SP Elliot (2004) Nonfatal instances of intoxication with gammahydroxybutyrate in the United Kingdom. Ther Drug Monit 26(4), 432-440.
53. O Miro, S Nogue, G Espinosa, et al. (2002) Trends in illicit drug emergencies: the emerging role of gammahydroxybutyrate. J Toxicol Clin Toxicol 40(2), 129-135.
54. ME Liechti and H Kupferschmidt (2004) γ-Hydroxybutyrate (GHB) and γ-butyrolactone (GBL): analysis of overdose cases reported to the Swiss Toxicological Information Centre. Swiss Med Wkly 134 534-537.
55. IJ Bosman and KJ Lusthof (2003) Forensic cases involving the use of GHB in the Netherlands. Forensic Sci Int 133(1–2), 17-21.
56. DGE Caldicott, FY Chow, BJ Burns, et al. (2004) Fatalities associated with the use of γ-hydroxybutyrate and its analogues in Australasia. Med J Aust 181(6), 310-313.
57. TCK Brown (2004) Epidemic of γ-hydroxybutyrate (GHB) ingestion. Med J Aust 181(6), 343.
58. Drug Enforcement Administration, Office of Diversion Control, Drug and Chemical Evaluation Section (August 11, 2000) Fact sheet: gamma hydroxybutyric acid (GHB, liquid X, goop, Georgia home boy). DEA/ODE #(000811) Washington, DC: Drug Enforcement Administration
59. Drug Enforcement Agency, U.S. Department of Justice: GHB/GBL. Retrieved March 2005 from http://www.usdoj.gov/dea/concern/drug_trafficking.html.
60. National Drug Intelligence Center, U.S. Department of Justice (August 2002) Information bulletin: GHB analogs: GBL, BD, GHV, and GVL. Product no. 2002-L0424–003 Washington, DC: National Drug Intelligence Center
61. National Drug Intelligence Center, U.S. Department of Justice (September 2004) Intelligence bulletin: GHB trafficking and abuse. Product no. 2004-L0424–015 Washington, DC: National Drug Intelligence Center
62. DL Zvosec and SW Smith (2003) Unsupported “efficacy” claims of gamma hydroxybutyrate (GHB). Acad Emerg Med 10(1), 95-96.
63. MA ElSohly and SJ Salamone (1999) Prevalence of drugs used in cases of alleged sexual assault. J Anal Toxicol 23 141-146.
64. F Henretig, C Vassalluzo, K Osterhoudt, et al. (1998) “Rave by net”: gammahydroxybutyrate (GHB) toxicity from kits sold to minors via the internet [Abstract]. J Toxicol Clin Toxicol 36 503.
65. B Cartigny, N Azaroual, M Imbenotte, et al. (2001) 1H NMR spectroscopic investigation of serum and urine in a case of acute tetrahydrofuran poisoning. J Anal Toxicol 25 270-274.
66. J Benavides, JF Rumigny, JJ Bourguignon, et al. (1982) A high-affinity, Na+-dependent uptake system for gammahydroxybutyrate in membrane vesicles prepared from rat brain. J Neurochem 38(6), 1570-1575.
67. JJ Bourguignon, A Schoenfelder, M Schmitt, et al. (1988) Analogues of γ-hydroxybutyric acid. Synthesis and binding studies. J Med Chem 31(5), 893-897.
68. JJ Bourguignon, M Schmitt and B Didier (2000) Design and structure-activity relationship analysis of ligands of gamma-hydroxybutyric acid receptors. Alcohol 20 227-236.
69. P Vayer and M Maitre (1988) Regional differences in depolarization-induced release of γ-hydroxybutyrate from rat brain slices. Neurosci Lett 87 99-103.
70. M Mamelak (1989) Gammahydroxybutyrate: an endogenous regulator of energy metabolism. Neurosci Biobehav Rev 13 187-198.
71. M Maitre (1997) The γ-hydroxybutyrate signaling system in brain: organization and functional implications. Prog Neurobiol 51 337-361.
72. OC Snead (1987) γ-Hydroxybutyric acid in subcellular fractions of rat brain. J Neurochem 48 196-201.
73. RH Roth and NJ Giarman (1968) Evidence that central nervous system depression by 1,4-butanediol is mediated through a metabolite, gammahydroxybutyrate. Biochem Pharmacol 17 735-739.
74. BI Gold and RH Roth (1977) Kinetics of in vivo conversion of γ-[3H]aminobutyric acid to γ-[3H]hydroxybutyric acid by rat brain. J Neurochem 28 1069-1073.
75. OC Snead 3rd, R Furner and CC Liu (1989) In vivo conversion of gamma-aminobutyric acid and 1,4-butanediol to gamma-hydroxybutyric acid in rat brain. Studies using stable isotopes. Biochem Pharmacol 38(24), 4375-4380.
76. M Eli and F Cattabeni (1983) Endogenous γ-gammahydroxybutyrate in rat brain areas: postmortem changes and effects of drugs interfering with γ-aminobutyric acid metabolism. J Neurochem 41 524-530.
77. CG Wong, KF Chan, KM Gibson, et al. (2004) γ-Hydroxybutyric acid: neurobiology and toxicology of a recreational drug. Toxicol Rev 23(1), 3-20.
78. CG Wong, KM Gibson and OC Snead 3rd (2004) From the street to the brain: neurobiology of the recreational drug γ-hydroxybutyric acid. Trends Pharmacol Sci 25(1), 29-34.
79. JF Rumigny, C Cash, P Mandel, et al. (1981) Evidence that a specific succinic semialdehyde reductase is responsible for γ-hydroxybutyrate synthesis in brain tissue slices. FEBS Lett 134 96-98.
80. CD Cash, M Maitre and P Mandel (1979) Purification from human brain and some properties of two NADPH-linked aldehyde reductases which reduce succinic semialdehyde to 4-hydroxybutyrate. J Neurochem 33 1169-1175.
81. P Vayer, M Schmitt, JJ Bourguignon, et al. (1985) Evidence for a role of high Km aldehyde reductase in the degradation of endogenous γ-hydroxybutyrate from rat brain. FEBS Lett 190 55-60.
82. D Weissmann-Nanopoulos, MF Belin, P Mandel, et al. (1984) Immunocytochemical evidence for the presence of enzymes synthesizing GABA and GHB in the same neuron. Neurochem Int 6 333-338.
83. D Weissmann-Nanopoulos, JF Rumigny, P Mandel, et al. (1982) Immunocytochemical localization in rat brain of the enzyme that synthesizes γ-hydroxybutyric acid. Neurochem Int 4 523-529.
84. JF Rumigny, C Cash, P Mandel, et al. (1982) Ontogeny and distribution of specific succinic semialdehyde reductase apoenzyme in the rat brain. Neurochem Res 7 555-561.
85. JF Rumigny, M Maitre, C Cash, et al. (1981) Regional and subcellular localization in rat brain of the enzymes that can synthesize γ-hydroxybutyric acid. J Neurochem 36 1433-1438.
86. SA Barker, OC Snead, F Poldrugo, et al. (1985) Identification and quantitation of 1,4-butanediol in mammalian tissues: an alternative biosynthesis pathway for gamma-hydroxybutyric acid. Biochem Pharmacol 34 1849-1852.
87. R Pietruszko, K Voigtlander and D Lester (1978) Alcohol dehydrogenase from human and horse liver-substrate specificity with diols. Biochem Pharmacol 27 1296-1297.
88. R Maxwell and RH Roth (1972) Conversion of 1,4-butanediol to gamma-hydroxybutyric acid in rat brain and in peripheral tissue. Biochem Pharmacol 21 1521-1533.
89. NJ Tillakaratne, L Medina-Kauwe and KM Gibson (1995) Gamma-aminobutyric acid (GABA) metabolism in mammalian neural and nonneural tissues. Comp Biochem Physiol A 112(2), 247-263.
90. JD Doherty, SE Hattox, OC Snead, et al. (1975) A sensitive method for quantitation of γ-hydroxybutyric acid and γ-butyrolactone in brain by electron capture gas chromatography. Anal Biochem 69 268-277.
91. RH Roth, JMR Delgado and NJ Giarman (1966) Gamma-butyrolactone and gamma-hydroxybutyric acid. II. The pharmacologically active form. Int J Neuropharmacol 5 421-428.
92. WN Fishbein and SP Bessman (1966) Purification and properties of an enzyme in human blood and rat liver microsomes catalyzing the formation and hydrolysis of γ-lactones. J Biol Chem 241 4835-4841.
93. M Maitre and P Mandel (1982) Liberation de γ-hydroxybutyrate calcium-dependente après depolarisation de coupes de cerveau de rat. C R Acad Sci Paris 295 741-743.
94. M Maitre, C Cash, D Weissmann-Nanopoulos, et al. (1983) Depolarization-evoked release of γ-hydroxybutyrate from rat brain slices. J Neurochem 41 287-290.
95. P Vayer and M Maitre (1988) Regional differences in depolarization-induced release of γ-hydroxybutyrate from rat brain slices. Neurosci Lett 87 99-103.
96. J Benavides, JF Rumigny, JJ Bourguignon, et al. (1982) High affinity binding sites for gamma-hydroxybutyric acid in rat brain. Life Sci 30 953-961.
97. M Maitre, JF Rumigny, J Benavides, et al. (1983) High affinity binding site for gamma-hydroxybutyric acid in rat brain. Adv Biochem Psychopharmacol 37 441-453.
98. OC Snead and CC Liu (1984) Gamma-hydroxybutyric acid binding sites in rat and human brain synaptosomal membranes. Biochem Pharmacol 33 2587-2590.
99. C Andriamampandry, O Taleb, S Viry, et al. (2003) Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator γ-hydroxybutyrate (GHB). FASEB J 17 1691-1693.
100. P Vayer and M Maitre (1989) γ-Hydroxybutyrate stimulation of the formation of cyclic GMP and inositol phosphates in rat hippocampal slices. J Neurochem 52 1382-1387.
101. PK Banerjee and OC Snead III (1995) Presynaptic gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB (GABAB) receptor-mediated release of GABA and glutamate (GLU) in rat thalamic ventrobasal nucleus (VB): a possible mechanism for the generation of absence-like seizures induced by GHB. J Pharmacol Exp Ther 273 1534-1543.
102. S Gobaille, V Hechler, C Andriamampandry, et al. (1999) γ-Hydroxy-butyrate modulates synthesis and and extracellular concentration of γ-aminobutyratic acid in discrete rat brain regions in vivo. J Pharmacol Exp Ther 290 303-309.
103. RH Roth, JD Doherty and JR Walters (1980) Gammahydroxybutyrate: a role in the regulation of central dopaminergic neurons? Brain Res 189 556-560.
104. V Hechler, S Gobaille, J Bourguignon, et al. (1991) Extracellular events induced by gammahydroxybutyrate in striatum: a microdialysis study. J Neurochem 56 938-944.
105. SG Howard and JJ Feigenbaum (1997) Effect of γ-hydroxybutyrate on central dopamine release in vivo. Biochem Pharmacol 53 103-110.
106. JR Walter and RH Roth (1972) Effect of gammahydroxybutyrate on dopamine and dopamine metabolites in the rat striatum. Biochem Pharmacol 21 2111-2121.
107. V Morgenroth, JR Walters and R Roth (1976) Dopaminergic neurons—alteration in the kinetic properties of tyrosine hydroxylase after cessation of impulse flow. Biochem Pharmacol 25 655-661.
108. H Nissbrandt, A Elverfors and G Enberg (1994) Pharmacologiclly induced cessation of burst activity in nigral dopamine neurons: significance for the terminal dopamine efflux. Synapse 17 217-224.
109. PC Waldmeier and B Fehr (1978) Effects of baclofen and γ-hydroxybutyrate on rat striatal and mesolimbic 5-HT metabolism. Eur J Pharmacol 49 177-184.
110. T Hedner and P Lundborg (1983) Effect of gammahydroxubutyric acid on serotonin synthesis, concentration and metabolism in the developing rat brain. J Neural Trans 57 39-48.
111. NJ Giarman and KF Schmidt (1963) Some neurochemical aspects of the depressant action of gamma-butyrolactone on the central nervous system 1. Br J Pharmacol 20 563-568.
112. VH Sethy, RH Roth, JR Walters, et al. (1976) Effect of anesthetic doses of γ-hydroxybutyrate on the acetylcholine content of rat brain. Naunyn Schmiedebergs Arch Pharmacol 295 9-14.
113. H Ladinsky, S Consolo, A Zatta, et al. (1983) Mode of action of gamma-butyrolactone on the central cholinergic system. Naunyn Schmiedebergs Arch Pharmacol 322 42-48.
114. JJ Feigenbaum and R Simatov (1996) Lack of effect of γ-hydroxybutyrate on μ, κ, and δ opioid receptor binding. Neurosci Lett 212 5-8.
115. W Larson, B Przewlocka and R Przewlocka (1983) The effect of gammahydroxybutyrate and anticonvulsants on opioid peptide content in the rat brain. Life Sci 33 599-602.
116. S Gobaille, C Schmidt, A Cupo, et al. (1994) Characterization of methionine-enkephalin release in the rat striatum by in vivo dialysis: effects of gamma-hydroxy butyrate on cellular and extracellular methionine enkephalin levels. Neuroscience 60 637-648.
117. OC Snead III and LJ Bearden (1980) Naloxone overcomes the dopaminergic, EEG, and behavioral effects of γ-hydroxybutyrate. Neurology 30 832-838.
118. JJ Feigenbaum and SG Howard (1997) Naloxone reverses the inhibitory effects of γ-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis study. Neurosci Lett 224 71-74.
119. C Muller, S Viry, M Miehe, et al. (2002) Evidence for a gammahydroxybutyrate (GHB) uptake by rat brain synaptic vesicles. J Neurochem 80(5), 899-904.
120. V Hechler, JJ Bourguignon, CG Wermuth, et al. (1985) γ-Hydroxybutyrate uptake by rat brain striatal slices. Neurochem Res 10 387-396.
121. KL Chambliss and KM Gibson (1992) Succinic semialdehyde dehydrogenase from mammalian brain: subunit analysis using polyclonal antiserum. Int J Biochem 24 1493-1499.
122. RK Margolis (1969) The effect of γ-hydroxybutyric acid on amino-acid levels in brain. Biochem Pharmacol 18 1243-1246.
123. JD Doherty, RW Stout and RH Roth (1975) Metabolism of [1-14C]γ-hydroxybutyric acid by rat brain after intraventricular injection. Biochem Pharmacol 24 469-474.
124. G Della Pietra, G Illiano, V Capano, et al. (1966) In vivo conversion of γ-hydroxybutyrate into γ-aminobutyrate. Nature 210 733-734.
125. FV De Feudis and B Collier (1970) Conversion of γ-hydroxybutyrate to γ-aminobutyrate by mouse brain in vivo. Experientia 26 1072-1073.
126. P Vayer, P Mandel and M Maitre (1985) Conversion of γ-hydroxybutyrate to γ-aminobutyrate in vitro. J Neurochem 45 810-814.
127. OC Snead (1987) γ-Hydroxybutyric acid in subcellular fractions of rat brain. J Neurochem 48 196-201.
128. V Chan-Palay, JY Wu and SL Palay (1979) Immunocytochemical localization of γ-aminobutyric acid transaminase at cellular and ultrastructural levels. Proc Natl Acad Sci U S A 76 2067-2071.
129. JM Walsh and JB Clark (1976) Studies on the control of 4-aminobutyrate metabolism in synaptosomal and free rat brain mitochondria. Biochem J 160 147-157.
130. M Bloch-Tardy, A Buzenet, C Fages, et al. (1980) Two forms of GABA-T in pig brain. Purification and properties. Neurochem Res 5 1147-1154.
131. SR Vincent, H Kimura and EG McGreer (1981) The histochemical localization of GABA transaminase in the efferents of the striatum. Brain Res 222 198-203.
132. SS Walkenstein, R Wiser, C Gudmundsen, et al. (1964) Metabolism of γ-hydroxybutyratic acid. Biochem Biophys Acta 86 640-642.
133. T Niwa, K Maeda, H Asada, et al. (1982) Gas chromatographic-mass spectrometric analysis of organic acids in renal tissue biopsy: 4-hydroxybutyric acid and 4-hydroxy-2-butenoic acid. J Chromatogr 230 1-6.
134. P Vayer, JD Ehrhardt, S Gobaille, et al. (1988) Gamma hydroxybutyrate distribution and turnover rates in discrete brain regions of the rat. Neurochem Int 12 53-59.
135. C Jakobs, M Bojasch, E Monch, et al. (1981) Urinary excretion of gamma-hydroxybutyric acid in a patient with neurologic abnormalities. The probability of a new inborn error of metabolism. Clin Chim Acta 111 169-178.
136. V Hechler, M Schmitt, JJ Bourguignon, et al. (1990) Trans-gamma-hydroxycrotonic acid binding sites in brain: evidence for a subpopulation of of gammahydroxybutyrate sites. Neurosci Lett 110 204-209.
137. V Hechler, P Peter, S Gobaille, et al. (1993) Gammahydroxybutyrate ligands possess antidopaminergic and neuroleptic-like activities. J Pharmacol Exp Ther 264 1406-1414.
138. EE Kaufman, T Nelson, HM Fales, et al. (1988) Isolation and characterization of a hydroxyacid-oxoacid transhydrogenase from rat kidney mitchondria. J Biol Chem 263 16872-16879.
139. GK Brown, CH Cromby, NJ Manning, et al. (1987) Urinary organic acids in succinic semialdehyde dehydrogenase deficiency: evidence of alpha-oxidation of 4-hydroxybutyric acid, interaction of succinic semialdehyde with pyruvate dehydrogenase and possible secondary inhibition of mitochondrial beta-oxidation. J Inherit Metab Dis 10 367-375.
140. KM Gibson and C Jakobs (2001) Disorders of beta- and gamma-amino acids in free and peptide-linked forms. CR Scriver, AL Beaudet, WS Sly, D Valle (Eds) The Metabolic and Molecular Bases of Inherited Disease New York: McGraw-Hill 2079-2105.
141. HR Olpe and WP Koella (1979) Inhibition of nigral and neocortical cells by γ-hydroxybutyrate: a microiontophoretic investigation. Eur J Pharmacol 53 359-364.
142. SX Kozhechkin (1980) Microiontophoretic study of the mechanism of action of gamma-hydroxybutyric acid. Bull Exp Biol Med 88 1293-1296.
143. L Hosli, E Hosli, R Lehmann, et al. (1983) Action of γ-hydroxybutyrate and GABA on neurons of cultured rat central nervous system. Neurosci Lett 37 257-260.
144. OC Snead and CC Liu (1993) GABAA receptor function in the gammahydroxybutyrate model of generalized absence seizures. Neuropharmacology 32 401-409.
145. SR Williams, JP Turner and V Crunelli (1995) Gammahydroxybutyrate promotes oscillatory activity of rat and cat thalamocortical neurons by a tonic GABABreceptor-mediated hyperpolarization. Neuroscience 66 133-141.
146. X Xie and TG Smart (1992) γ-Hydroxybutyrate hyperpolarizes hippocampal neurons by activating GABAB receptors. Eur J Pharmacol 212 291-294.
147. K Lingenhoehl, R Brom, J Heid, et al. (1999) γ-Hydroxybutyrate is a weak agonist at recombinant GABAB receptors. Neuropharmacology 38 1667-1673.
148. Z Emri, K Antal, C Crunelli, et al. (1996) Gamma-hydroxybutyric acid decreases thalamic sensory excitatory postsynaptic potentials by an action on presynaptic GABABreceptors. Neurosci Lett 216 121-124.
149. S Erhardt, B Andersson, H Nissbrandt, et al. (1998) Inhibition of firing rate and changes in the firing pattern of nigral dopamine neurons by γ-hydroxybutyratic acid (GHBA) are specifically induced by activation of GABAB receptors. Naunyn Schmiedebergs Arch Pharmacol 357 611-619.
150. LS Quang, MC Desai, JC Kraner, et al. (2002) Enzyme and receptor antagonists for preventing toxicity from the gamma-hydroxy-butyric acid precursor 1,4-butanediol in CD-1 mice. Ann NY Acad Sci 965 461-472.
151. MAM Carai, G Colombo, R Reali, et al. (2002) Central effects of 1,4-butanediol are mediated by GABAB receptors via its conversion into γ-hydroxybutyric acid. Eur J Pharmacol 441 157-163.
152. MAM Carai, G Colombo, G Brunetti, et al. (2001) Role of GABAB receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid. Eur J Pharmacol 428 315-321.
153. MAM Carai, G Colombo and GL Gessa (2005) Resuscitative effect of a GABAB receptor antagonist on γ-hydroxybutyric acid (GHB) mortality in mice. Ann Emerg Med 45 614-619.
154. BM Hogema, M Taylor, C Jakobs, et al. (2001) Pharmacologic rescue of lethal seizures in mice deficient in succinic semialdehyde dehydrogenase. Nat Genet 29 212-216.
155. P Mathivet, R Bernasconi, W Froestl, et al. (1997) Binding characteristics of gamma-hydroxybutyric acid as a weak but selective GABAB receptor agonist. Eur J Pharmacol 321 67-75.
156. JD Doherty, SE Hattox and OC Snead (1978) Identification of endogenous γ-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig, and rhesus monkey brain. J Pharmacol Exp Ther 207 130-139.
157. V Hechler, C Ratomponirina and M Maitre (1997) Gammahydroxybutyrate conversion into GABA induces displacement of GABAB binding that is blocked by valproate and ethosuxisimide. J Pharmacol Exp Ther 281 753-760.
158. P Palatini, L Tedeschi, G Frison, et al. (1993) Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 45 353-356.
159. Orphan Medical, Inc. (2001) NDA #21–196 Xyrem (sodium oxybate) oral solution. Peripheral and Central Nervous System Drugs Advisory Committee Briefing Booklet for June 6, 2001, presentation Minnetonka, MN: Orphan Medical, Inc. 201-220.
160. LA Borgen, R Okerholm, D Morrison, et al. (2003) The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol 43 59-65.
161. R Brenneisen, MA ElSohly, TP Murphy, et al. (2004) Pharmacokinetics and excretion of gammahydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 28(8), 625-630.
162. LA Borgen, RA Okerholm, A Lai, et al. (2004) The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. J Clin Pharmacol 44 253-257.
163. MB Scharf, AA Lai, B Branigan, et al. (1998) Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 21(5), 507-514.
164. SD Ferrara, L Tedeschi, G Frison, et al. (1996) Effect of moderate or severe liver dysfunction on the pharmacokinetics of γ-hydroxybutyric acid. Eur J Clin Pharmacol 50(4), 305-310.
165. SD Ferrara, S Zotti, L Tedeschi, et al. (1992) Pharmacokinetics of gammahydroxybutyrate in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 34 231-235.
166. TB Vree, AM Baars and E Van Der Kleijn (1975) Capacity-limited elimination of 4-hydroxybutyrate (Gamma OH®), ethanol and vinylbital (Bykonox®). Pharmaceutisch Weekblad 110(50), 1257-1262.
167. TB Vree, J Damsma, AG Van den Bogert and E van Der Kleijn (1978) Pharmocokinetics of 4-hydroxybutyric acid in man, rhesus monkey and dog. Anaesthesiol Intensive Med 110 21-39.
168. AG van den Bogert, TB Vree, E van den Kleijn, et al. (1978) Placenta transfer of 4-hydroxybutyric acid in man. Anaesthesiol Intensive Med 110 55-65.
169. M Blumenfeld, RG Suntay and MH Harmel (1962) Sodium gamma-hydroxybutyric acid: a new anaesthetic adjuvant. Anesth Analg 41 721-726.
170. J Solway and MS Sadove (1965) 4-Hydroxybutyrate: a clinical study. Anesth Analg 44 532-539.
171. S Kleinschmidt, U Grundmann, U Janneck, et al. (1997) Total intravenous anesthesia using propofol, gammahydroxybutyrate or midazolam in combination with sufentanil for patients undergoing coronary artery bypass surgery. Eur J Anaesthesiol 14 590-599.
172. S Kleinschmidt, U Grundmann, T Knocke, et al. (1998) Total intravenous anaesthesia with gammahydroxybutyrate (GHB) and sufentanil in patients undergoing coronary artery bypass graft surgery: a comparison in patients with unimpaired and impaired left ventricular function. Eur J Anaesthesiol 15 559-564.
173. S Kleinschmidt, C Schellhase and F Mertzufft (1999) Continuous sedation during spinal anaesthesia: gammahydroxybutyrate vs propofol. Eur J Anaesthesiol 16 23-30.
174. European Monitoring Centre for Drugs and Drug Addiction: Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs. Retrieved April 2005 from http://www.emcdda.eu.int/?nnodeid=2821.
175. R Broughton and M Mamelak (1979) The treatment of narcolepsy-cataplexy with nocturnal γ-hydroxybutyrate. Can J Neurol Sci 6 1-6.
176. M Scharf, D Brown, M Woods, et al. (1985) The effects and effectiveness of γ-hydroxybutyrate in patients with narcolepsy. J Clin Psychiatry 46 222-225.
177. MA Bedard, J Montplaisir, R Godbout, et al. (1989) Nocturnal γ-hydroxybutyrate: effect on periodic leg movements and sleep organization of narcoleptic patients. Clin Neuropharmacol 12 29-36.
178. L Scrima, PG Hartman, FH Johnson, et al. (1990) The effects of γ-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep 13 479-490.
179. GJ Lammers, J Arends, AC Declerck, et al. (1993) γ-Hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 6 216-220.
180. U.S. Xyrem Multicenter Study Group (2002) A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 25 42-49.
181. Orphan Medical, Inc. (2002) Xyrem physician's monograph Minnetonka, MN: Orphan Medical, Inc.
182. U.S. Xyrem Multicenter Study Group (2003) The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol 41 131-135.
183. U.S. Xyrem Multicenter Study Group (2003) A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 26 31-35.
184. L Gallimberti, MR Spella, CA Soncini, et al. (2000) Gamma-hydroxybutric acid in the treatment of alcohol and heroine dependence. Alcohol 20 257-262.
185. L Gallimberti, G Canton, N Gentile, et al. (1989) Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 2 787-789.
186. L Gallimberti, M Ferri, SD Ferrara, et al. (1992) Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double blind study. Alcohol Clin Exp Res 16 673-676.
187. G Addolorato, M Cibin, E Capristo, et al. (1999) Maintaining abstinence from alcohol with gamma-hydroxybutyric acid. Lancet 351(9095), 38.
188. G Addolorato, E Castelli, GF Stefanini, et al. (1996) An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. Alcohol Alcoholism 31 341-345.
189. M Mamelak, J Black, J Montplaisir, et al. (2004) A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 27(7), 1327-1334.
190. MB Scharf, M Baumann and DV Berkowitz (2003) The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 30 1070-1074.
191. MB Scharf, M Hauck, R Stover, et al. (1998) Effect of gammahydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report. J Rheumatol 25 1986-1990.
192. A Ottani, S Saltini, M Bartiromo, et al. (2003) Effect of gammahydroxybutyrate in two rat models of focal cerebral damage. Brain Res 986(1–2), 181-190.
193. AV Vergoni, A Ottani, AR Botticelli, et al. (2000) Neuroprotective effect of gammahydroxybutyrate in transient global cerebral ischemia in the rat. Eur J Pharmacol 397(1), 75-84.
194. LS Quang, S Sadasivan, TJ Maher, et al. (2003) Neuroprotective effect of gammahydroxybutyrate and its chemical precursors, gamma-butyrolactone and 1,4-butanediol, in the rodent model of focal cerebral ischemia by permanent middle cerebral artery occlusion [Abstract]. Acad Emerg Med 10(5), 438.
195. LS Quang, S Sadasivan and TJ Maher (2003) Neuroprotective effects of gammahydroxybutyrate and its precursors 1,4-butanediol and gamma-butyrolactone in MCAo cerebral ischemia [Abstract]. FASEB J 17(4–5), 391. 12.
196. A Yosunkaya, ME Ustun, H Bariskaner, et al. (2004) Effect of gamma-hydroxybutyric acid on tissue Na+, K-ATPase levels after experimental head trauma. Acta Anaesthesiol Scand 48(5), 631-636.
197. O Guney, J Bengi Celik, M Arazi, et al. (2004) Effects of gammahydroxybutyrate on cerebrospinal fluid lactate and glucose levels after spinal cord trauma. J Clin Neurosci 11(5), 517-520.
198. K Yonekura, Y Basaki, L Chikahisa, et al. (1999) UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 5 2185-2191.
199. Y Basaki, L Chikahisa, K Aoyagi, et al. (2001) Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 4(3), 163-173.
200. Orphan Medical, Inc.: Covance study no. 6627-129, Xyrem (sodium oxybate) oral solution NDA #21-196. Briefing Booklet for the Peripheral and Central Nervous System Drugs Advisory Committee Meeting for June 6, 2001, presentation. Minnetonka, MN, Orphan Medical, Inc., 2001.
201. S Suner, CS Szlatenyi and RY Wang (1997) Pediatric gamma hydroxybutyrate intoxication. Acad Emerg Med 4(11), 1041-1045.
202. JE Dyer and JH Reed (1997) Alkali burns from illicit manufacture of GHB [Abstract]. J Toxicol Clin Toxicol 35 553.
203. GP Galloway, SL Frederick and F Staggers Jr (1994) Physical dependence on sodium oxybate [Letter]. Lancet 343 57.
204. J Friedman, R Westlake and M Furman (1996) “Grievous bodily harm”: gamma hydroxybutyrate abuse leading to Wernicke-Korsakoff syndrome. Neurology 46 469-471.
205. G Addolorato, F Caputo, GF Stefanini, et al. (1997) Gamma-hydroxybutyric acid in the treatment of alcohol dependence: possible craving development for the drug [see comment]. Addiction 92(8), 1035-1036.
206. GP Galloway, SL Frederick-Osborne, R Seymour, et al. (1997) Gammahydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 92 89-96.
207. JE Dyer and KM Andrews (1997) Gamma hydroxybutyrate withdrawal. J Toxicol Clin Toxicol 92 89-96.
208. GP Galloway, SL Frederick, FE Staggers Jr, et al. (1997) Gammahydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 92 89-96.
209. M Hernandez, CH McDaniel, CD Costanza, et al. (1998) GHB-induced delirium: a case report and review of the literature of gamma hydroxybutyric acid. Am J Drug Alcohol Abuse 24 179-183.
210. G Addolorato, F Caputo, E Capristo, et al. (1999) A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: utility of diazepam administration. Clin Neuropharmacol 22(1), 60-62.
211. G Price (2000) Inpatient detoxification after GHB dependence. Br J Psychiatry 177 181.
212. K Craig, HF Gomez, JL McManus, et al. (2000) Severe gammahydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 18(1), 64-70.
213. B Hutto, A Fairchild and R Bright (2000) γ-Hydroxybutyrate withdrawal and chloral hydrate. Am J Psychiatry 157 10.
214. JS Miglani, KY Kim and R Chahil (2000) Gammahydroxybutyrate withdrawal delirium: a case report. Gen Hosp Psychiatry 22 213-215.
215. G Price (2000) Inpatient detoxification after GHB dependence. Br J Psychiatry 177 181.
216. T Greene and T Dougherty (2000) Gamma-butyrolactone withdrawal presenting as acute psychosis. J Toxicol Clin Toxicol 37 651.
217. AN Sharma, L Nelson and RS Hoffman (2000) Severe gamma-butyrolactone withdrawal. J Toxicol Clin Toxicol 38 535.
218. MC Catalano, JM Glass, G Catalano, et al. (2001) Gamma butyrolactone (GBL) withdrawal syndromes. Psychosomatics 42(1), 83-88.
219. ME Mullins and SC Fitzmaurice (2001) Lack of efficacy of benzodiazepines in treating gammahydroxybutyrate withdrawal. J Emerg Med 20(4), 418-420.
220. AN Sharma and MH Lombardi (2001) Management of gammahydroxybutyrate withdrawal. Ann Emerg Med 38(5), 605-607.
221. M Su, SJ Traub, E Hussain, et al. (2001) 1,4-Butanediol withdrawal complicated by urinary retention. J Toxicol Clin Toxicol 39 542.
222. TM Bowles, RW Sommi and M Amiri (2001) Successful management of prolonged γ-hydroxybutyrate and alcohol withdrawal. Pharmacotherapy 21(2), 254-257.
223. JE Dyer, B Roth and BA Hyma (2001) Gammahydroxybutyrate withdrawal syndrome. Ann Emerg Med 37(2), 147-153.
224. G Mahr, CL Bishop and DJ Orringer (2001) Prolonged withdrawal from extreme gammahydroxybutyrate (GHB) abuse. Psychosomatics 42(5), 439-440.
225. CH McDaniel and KA Miotto (2001) Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs 33(2), 143-149.
226. K Miotto, J Darakjian, J Basch, et al. (2001) Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 10 232-241.
227. AB Schneir, BT Ly and RF Clark (2001) A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med 21(1), 31-33.
228. ML Sivilotti, MJ Burns, CK Aaron, et al. (2001) Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med 38(6), 660-665.
229. MB Mycyk, C Wilemon and SE Aks (2001) Two cases of withdrawal from 1,4-butanediol use. Ann Emerg Med 38(3), 345-346.
230. RL Chin (2001) A case of severe withdrawal from gammahydroxybutyrate. Ann Emerg Med 37(5), 551-552.
231. AH Harold and KB Sneed (2002) Treatment of a young adult taking gamma-butyrolactone (GBL) in a primary care clinic. J Am Board Fam Pract 15(2), 161-163.
232. DL Zvosec and SW Smith (2004) γ-Hydroxybutyrate addiction and withdrawal: From the γ-hydroxybutyrate addiction study. Ann Emerg Med 44(4), pS91.
233. G Chew and A Fernando 3rd (2004) Epileptic seizure in GHB withdrawal. Aust Psychiatry 12(4), 410-411.
234. DC De Vivo, KM Gibson, LD Resor, et al. (1988) 4-Hydroxybutyric acidemia: clinical features, pathogenetic mechanisms, and treatment strategies. Ann Neurol 24(2), 304.
235. PP Pattarelli, WL Nyhan and KM Gibson (1988) Oxidation of [U-14C] succinic semialdehyde in cultured human lymphoblasts: measurement of residual succinic semialdehyde dehydrogenase activity in 11 patients with 4-hydroxybutyric aciduria. Pediatr Res 24(4), 455-460.
236. EA Haan, GK Brown, D Mitchell, et al. (1985) Succinic semialdehyde dehydrogenase deficiency—a further case. J Inherit Metab Dis 8 99.
237. C Jakobs, LM Smit, J Kneer, et al. (1990) The first adult case with 4-hydroxybutyric aciduria. J Inherit Metab Dis 13 341-344.
238. KM Gibson, L Sweetman, WL Nyhan, et al. (1984) Defective succinic semialdehyde dehydrogenase activity in 4-hydroxybutyric aciduria. Eur J Pediatr 142 257-259.
239. KM Gibson, CF Lee, KL Chambliss, et al. (1991) 4-Hydroxybutyric aciduria: application of a fluorometric assay to the determination of succinic semialdehyde dehydrogenase activity in extracts of cultured human lymphoblasts [Letter]. Clin Chim Acta 196 219-222.
240. KM Gibson, SI Goodman, FE Frerman, et al. (1989) Succinic semialdehyde dehydrogenase deficiency associated with combined 4-hydroxbutyric and dicarboxylic acidurias: potential for clinical misdiagnosis based on urinary organic acid profiling. J Pediatr 114(4), 607-610.
241. KM Gibson, AE Doskey, C Jakobs, et al. (1997) Differing clinical presentation of succinic semialdehyde dehydrogenase deficiency in adolescent siblings from Lifu Island, New Caledonia. J Inherit Metab Dis 20 370-374.
242. KM Gibson, G Hoffman, WL Nyhan, et al. (1988) 4-Hydroxybutyric aciduria in a patient without ataxia or convulsions. Eur J Pediatr 147 529-531.
243. KM Gibson, L Sweetman, WL Nyhan, et al. (1983) Succinic semialdehyde dehydrogenase deficiency: an inborn error of gamma-aminobutyric acid metabolism. Clin Chim Acta 133 33-42.
244. KM Gibson, I Jansen, L Sweetman, et al. (1984) 4-Hydroxybutyric aciduria: a new inborn error of metabolism. III. Enzymology and inheritance. J Inherit Metab Dis 7(Suppl 1), 95-96.
245. KM Gibson (2002) 4-Hydroxybutyric aciduria. G Tunnicliff, CD Cash (Eds) Gammahydroxybutyrate: Molecular, Functional and Clinical Aspects New York: Taylor & Francis 197-217.
246. F Trettel, P Malaspina, C Jodice, et al. (1996) Human succinic semialdehyde dehydrogenase: molecular cloning and chromosomal localization. Adv Exp Med Biol 414 253-260.
247. KL Chambliss, DD Hinson, F Trettel, et al. (1998) Two exon-skipping mutations as the molecular basis of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria). Am J Hum Genet 63 399-408.
248. D Rating, F Hanefeld, H Siemes, et al. (1984) 4-hydroxybutyric aciduria: a new inborn error of metabolism. I. Clinical review. J Inherit Metab Dis 7(Suppl 1), 90-92.
249. KM Gibson, E Christensen, C Jakobs, et al. (1997) The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients. Pediatrics 99(4), 567-574.
250. M LeBeau, MA Montgomery, RA Jufer, et al. (2000) Elevated GHB in citrate-buffered blood [Letter]. J Anal Toxicol 24 383-384.
251. MA LeBeau, ML Miller and B Levine (2001) Effect of storage temperature on endogenous GHB levels in urine. Forensic Sci Int 119(2), 161-167.
252. S Kerrigan (2002) In vitro production of gammahydroxybutyrate in antemortem urine samples. J Anal Toxicol 26(8), 571-574.
253. LA Ciolino, MZ Mesmer, D Satzger, et al. (2001) The chemical interconversion of GHB and GBL: forensic issues and implications. J Forensic Sci 46(6), 1315-1323.
254. BG Stephens, DE Coleman, RC Baselt, et al. (1999) In vitro stability of endogenous gammahydroxybutyrate in postmortem blood [Letter]. J Forensic Sci 44(1), 231-232.
255. S Elliot (2001) The presence of gamma-hydroxybutyric acid (GHB) in postmortem biological fluids [Letter]. J Anal Toxicol 25 152.
256. J Vose, T Tighe, M Schwartz, et al. (2001) Detection of gamma-butyrolactone (GBL) as a natural component in wine. J Forensic Sci 46(5), 1164-1167.
257. N Baddock and R Zotti (1999) Rapid screening test for gamma-hydroxybutyric acid (GHB, fantasy) in urine [Letter]. Ther Drug Monit 21(3), 376-377.
258. WC Alston II and K Ng (2002) Rapid colorimetric screening test for γ-hydroxybutyric acid (liquid X) in human urine. Forensic Sci Int 126 114-117.
259. CL Morris-Kukoski (2004) γ-Hydroxybutyrate: bridging the clinical-analytical gap. Toxicol Rev 23(1), 33-43.
260. KA Sporer, RL Chin, JE Dyer, et al. (2003) γ-Hydroxybutyrate serum levels and clinical syndrome after severe overdose. Ann Emerg Med 42 3-8.
261. LS Quang, HM Levy, T Law, et al. (2005) Laboratory diagnosis of 1,4-BD and GHB overdose by routine urine organic acid analysis. J Toxicol Clin Toxicol 43(4), 1-3.
262. DGE Caldicott and M Kuhn (2001) Gammahydroxybutyrate overdose and physostigmine: teaching new tricks to an old drug. Ann Emerg Med 37(1), 99-102.
263. RS Henderson and CM Holmes (1976) Reversal of the anesthetic action of sodium gammahydroxybutyrate. Anaesth Intensive Care 4(4), 351-354.
264. CM Holmes and RS Henderson (1978) The elimination of pollution by a non inhalational technique. Anaesth Intensive Care 6(2), 120-124.
265. B Persson and M Henning (1980) Central cardiovascular effects of gamma-hydroxybutyric acid; interactions with noradrenaline, serotonin, dopamine and acetylcholine transmission. Acta Pharmacol Toxicol (Copenh) 47 335-346.
266. ER McCabe, EC Layne, DF Sayler, et al. (1971) Synergy of ethanol and a natural soporific-gamma hydroxybutyrate. Science 171(969), 404-406.
267. F Poldrugo and OC Snead (1984) 1,4-Butanediol, gamma-hydroxybutyric acid, and ethanol: relationship and interaction. Neuropharmacology 23 109-113.
268. F Poldrugo, OC Snead and S Barker (1985) Chronic alcohol administration produces an increase in liver 1,4-butanediol concentration [Letter]. Alcohol Alcohol 20(2), 251-253.
269. F Poldrugo and OC Snead (1986) 1,4-Butanediol and ethanol compete for degradation in rat brain and liver in vitro. Alcohol 3(6), 367-370.
270. F Poldrugo and OC Snead (1983) Ethanol blocks the conversion of 1,4-butanediol to gamma-hydroxybutyric acid in vivo. Neurosci Abstr 9 1234.
271. F Poldrugo, S Barker, M Basa, et al. (1985) Ethanol potentiates the toxic effects of 1,4-butanediol. Alcohol Clin Exp Res 9(6), 493-497.
272. LS Quang, MW Shannon, AD Woolf, et al. (2002) Pretreatment of CD-1 mice with 4-methylpyrazole blocks toxicity from the gammahydroxybutyrate precursor, 1,4-butanediol. Life Sci 71 771-778.
273. LS Quang, MC Desai, MW Shannon, et al. (2004) 4-methylpyrazole decreases 1,4-butanediol toxicity by blocking its in vivo biotransformation to gamma-hydroxybutyric acid. Ann N Y Acad Sci 1025 528-537.
274. MA Carai, G Colombo, LS Quang, et al. (2006) Resuscitative treatments on 1,4-butanediol mortality in mice. Ann Emerg Med 47 184-189.